Cargando…

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer

To explore the parmacokinetics, safety and tolerability of paclitaxel after oral administration of SMEOF#3, a novel Self-Microemulsifying Oily Formulation, in combination with cyclosporin A (CsA) in patients with advanced cancer. Seven patients were enrolled and randomly assigned to receive oral pac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veltkamp, S A, Thijssen, B, Garrigue, J S, Lambert, G, Lallemand, F, Binlich, F, Huitema, A D R, Nuijen, B, Nol, A, Beijnen, J H, Schellens, J H M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360510/ https://www.ncbi.nlm.nih.gov/pubmed/16926835 http://dx.doi.org/10.1038/sj.bjc.6603312

Ejemplares similares

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
por: Hamaguchi, T, et al.
Publicado: (2005)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer
por: Schmidt, M, et al.
Publicado: (2007)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
por: Appels, N M G M, et al.
Publicado: (2008)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
por: Bouchet, B P, et al.
Publicado: (2007)

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
por: Vassileva, V, et al.
Publicado: (2008)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
por: Meulendijks, Didier, et al.
Publicado: (2017)

A leukotriene B(4) receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells
por: Kim, H, et al.
Publicado: (2013)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
por: Rajeshkumar, N V, et al.
Publicado: (2016)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
por: Reeder, A, et al.
Publicado: (2015)

Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
por: Sereni, Maria Isabella, et al.
Publicado: (2017)

(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
por: Yong, K J, et al.
Publicado: (2013)

Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
por: Yang, Q, et al.
Publicado: (2014)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer
por: Sun, S, et al.
Publicado: (2015)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
por: Vaidyanathan, Aparajitha, et al.
Publicado: (2016)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death
por: Obiorah, I, et al.
Publicado: (2014)

The role of apoptotic cell death in the radiosensitising effect of gemcitabine
por: Pauwels, B, et al.
Publicado: (2009)

Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase
por: Okada, F, et al.
Publicado: (2006)

In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation
por: Fanciullino, R, et al.
Publicado: (2007)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
por: Cambien, B, et al.
Publicado: (2009)

Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F
por: Le François, B G, et al.
Publicado: (2007)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
por: van Eijk, Maarten, et al.
Publicado: (2022)

CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver
por: Guillemot, E, et al.
Publicado: (2012)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8lbmbe0quavv5e9592gha04n5o